Fun for Avita

By Dylan Bushell-Embling
Wednesday, 16 July, 2008

Sales of Avita Medical's [AVH] respiratory products, including the Funhaler, increased 35 per cent last financial year, making up for the shelving of its CellSpray range of epithelial autograft products.

In a sales update released to the market, Avita said it had appointed pharmacy sales brokers Clear Sales as distributor of the Funhaler, an asthma device for children, for the Australian market earlier this year and is now actively searching for a US distributor following FDA approval last year.

Avita has also appointed a new senior sales executive, John Geisel, as senior vice-president of business development. He has over 35 years experience in medical sales and marketing.

Avita is the result of a merger between Clinical Cell Culture, which contributed the regenerative medicine product line, and Visiomed, an asthma device specialist with an eye on the ophthalmic market.

Related News

Frequent nightmares accelerate aging, increase risk of death

Nghtmares independently predict faster biological aging and earlier mortality — even after...

Cardiac organoids bring hope for treating heart disease

Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd